

Amy C Degnim

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3498292/publications.pdf>

Version: 2024-02-01

142
papers

6,334
citations

71102

41
h-index

76900

74
g-index

148
all docs

148
docs citations

148
times ranked

5709
citing authors

#	ARTICLE	IF	CITATIONS
1	Automated quantification of levels of breast terminal duct lobular (TDLU) involution using deep learning. <i>Npj Breast Cancer</i> , 2022, 8, 13.	5.2	6
2	Sexual Well-Being After Nipple-Sparing Mastectomy: Does Preservation of the Nipple Matter?. <i>Annals of Surgical Oncology</i> , 2022, 29, 4167-4179.	1.5	1
3	The breast tissue microbiome, stroma, immune cells and breast cancer. <i>Neoplasia</i> , 2022, 27, 100786.	5.3	9
4	ASO Visual Abstract: Sexual Well-Being After Nipple-Sparing Mastectomy: Does Preservation of the Nipple Matter?. <i>Annals of Surgical Oncology</i> , 2022, , .	1.5	0
5	Serum hormone levels and normal breast histology among premenopausal women. <i>Breast Cancer Research and Treatment</i> , 2022, , .	2.5	0
6	Towards defining morphologic parameters of normal parous and nulliparous breast tissues by artificial intelligence. <i>Breast Cancer Research</i> , 2022, 24, .	5.0	1
7	Impact of Personalized Genetic Breast Cancer Risk Estimation With Polygenic Risk Scores on Preventive Endocrine Therapy Intention and Uptake. <i>Cancer Prevention Research</i> , 2021, 14, 175-184.	1.5	11
8	Upgrade at excisional biopsy after a core needle biopsy diagnosis of classic lobular carcinoma in situ. <i>Surgery</i> , 2021, 169, 644-648.	1.9	9
9	Aurora-A kinase oncogenic signaling mediates TGF- β -induced triple-negative breast cancer plasticity and chemoresistance. <i>Oncogene</i> , 2021, 40, 2509-2523.	5.9	34
10	Automated Quantitative Measures of Terminal Duct Lobular Unit Involution and Breast Cancer Risk—Letter. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 797-797.	2.5	1
11	Surgical Management of Axilla Following Neoadjuvant Endocrine Therapy. <i>Annals of Surgical Oncology</i> , 2021, 28, 8729-8739.	1.5	6
12	Somatic mutations in benign breast disease tissues and association with breast cancer risk. <i>BMC Medical Genomics</i> , 2021, 14, 185.	1.5	2
13	ASO Visual Abstract: Surgical Management of Axilla Following Neoadjuvant Endocrine Therapy. <i>Annals of Surgical Oncology</i> , 2021, 28, 560-561.	1.5	1
14	Primary tumor resection in patients with stage IV breast cancer: 10-year experience. <i>Breast Journal</i> , 2021, 27, 863-871.	1.0	3
15	Cytotoxic T cell depletion with increasing epithelial abnormality in women with benign breast disease. <i>Breast Cancer Research and Treatment</i> , 2020, 180, 55-61.	2.5	4
16	Breast Cancer Risk and Use of Nonsteroidal Anti-inflammatory Agents After a Benign Breast Biopsy. <i>Cancer Prevention Research</i> , 2020, 13, 967-976.	1.5	9
17	Breast Reconstruction in the Setting of Stage 4 Breast Cancer: Is It Worthwhile?. <i>Annals of Surgical Oncology</i> , 2020, 27, 4730-4739.	1.5	5
18	Bioimpedance Spectroscopy of the Breast. <i>Lymphatic Research and Biology</i> , 2020, 18, 448-454.	1.1	3

#	ARTICLE	IF	CITATIONS
19	Intraoperative Pathologic Margin Analysis and Re-Excision to Minimize Reoperation for Patients Undergoing Breast-Conserving Surgery. <i>Annals of Surgical Oncology</i> , 2020, 27, 5303-5311.	1.5	15
20	Workload Differentiates Breast Surgical Procedures: NSM Associated with Higher Workload Demand than SSM. <i>Annals of Surgical Oncology</i> , 2020, 27, 1318-1326.	1.5	22
21	Prepectoral Two-Stage Implant-Based Breast Reconstruction with and without Acellular Dermal Matrix: Do We See a Difference?. <i>Plastic and Reconstructive Surgery</i> , 2020, 145, 263e-272e.	1.4	41
22	Rapid Generation of Sustainable HER2-specific T-cell Immunity in Patients with HER2 Breast Cancer using a Degenerate HLA Class II Epitope Vaccine. <i>Clinical Cancer Research</i> , 2020, 26, 1045-1053.	7.0	13
23	Single-Stage Direct-to-Implant Breast Reconstruction. <i>Annals of Plastic Surgery</i> , 2020, 84, 361-365.	0.9	40
24	Breast Atypia as a Biomarker of Risk. <i>Current Breast Cancer Reports</i> , 2019, 11, 95-99.	1.0	3
25	Mastectomy and immediate breast reconstruction in the elderly: Trends and outcomes. <i>Surgery</i> , 2019, 166, 709-714.	1.9	30
26	Outcomes of >1300 Nipple-Sparing Mastectomies with Immediate Reconstruction: The Impact of Expanding Indications on Complications. <i>Annals of Surgical Oncology</i> , 2019, 26, 3115-3123.	1.5	26
27	Two-Stage Implant-Based Breast Reconstruction: A Long-Term Outcome Study in a Young Population. <i>Medicina (Lithuania)</i> , 2019, 55, 481.	2.0	11
28	Bioinformatics and DNA-extraction strategies to reliably detect genetic variants from FFPE breast tissue samples. <i>BMC Genomics</i> , 2019, 20, 689.	2.8	37
29	Hyaline fibrous involution of breast lobules: a histologic finding associated with germline BRCA mutation. <i>Modern Pathology</i> , 2019, 32, 1263-1270.	5.5	1
30	Impact of short-term low-dose tamoxifen on molecular breast imaging background parenchymal uptake: a pilot study. <i>Breast Cancer Research</i> , 2019, 21, 38.	5.0	11
31	Surgical Outcomes of Prepectoral Versus Subpectoral Implant-based Breast Reconstruction in Young Women. <i>Plastic and Reconstructive Surgery - Global Open</i> , 2019, 7, e2119.	0.6	47
32	Infections following Immediate Implant-Based Breast Reconstruction: A Case-Control Study over 11 Years. <i>Plastic and Reconstructive Surgery</i> , 2019, 144, 1270-1277.	1.4	25
33	Risk Factors for Breast Carcinoma in Women With Proliferative Breast Disease. , 2018, , 264-271.e2.		1
34	Cellular fibroepithelial lesions of the breast: A long term follow up study. <i>Annals of Diagnostic Pathology</i> , 2018, 35, 85-91.	1.3	11
35	Benchmarking the American Society of Breast Surgeon Member Performance for More Than a Million Quality Measure-Patient Encounters. <i>Annals of Surgical Oncology</i> , 2018, 25, 501-511.	1.5	8
36	Influence of Biologic Subtype of Inflammatory Breast Cancer on Response to Neoadjuvant Therapy and Cancer Outcomes. <i>Clinical Breast Cancer</i> , 2018, 18, e501-e506.	2.4	19

#	ARTICLE	IF	CITATIONS
37	Oncologic Safety of Prophylactic Nipple-Sparing Mastectomy in a Population With <i>BRCA</i> Mutations. <i>JAMA Surgery</i> , 2018, 153, 123.	4.3	140
38	Macrophagic "Crown-like Structures" Are Associated with an Increased Risk of Breast Cancer in Benign Breast Disease. <i>Cancer Prevention Research</i> , 2018, 11, 113-119.	1.5	50
39	CD56+ immune cell infiltration and MICA are decreased in breast lobules with fibrocystic changes. <i>Breast Cancer Research and Treatment</i> , 2018, 167, 649-658.	2.5	5
40	Breast cancer-related paraneoplastic neurologic disease. <i>Breast Cancer Research and Treatment</i> , 2018, 167, 771-778.	2.5	20
41	When Does Atypical Ductal Hyperplasia Require Surgical Excision?. <i>Surgical Oncology Clinics of North America</i> , 2018, 27, 23-32.	1.5	16
42	Model for Predicting Breast Cancer Risk in Women With Atypical Hyperplasia. <i>Journal of Clinical Oncology</i> , 2018, 36, 1840-1846.	1.6	22
43	Select Choices in Benign Breast Disease: An Initiative of the American Society of Breast Surgeons for the American Board of Internal Medicine Choosing Wisely® Campaign. <i>Annals of Surgical Oncology</i> , 2018, 25, 2795-2800.	1.5	14
44	Evaluation of 2 breast cancer risk models in a benign breast disease cohort. <i>Cancer</i> , 2018, 124, 3319-3328.	4.1	7
45	Decreasing Use of Axillary Dissection in Node-Positive Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. <i>Annals of Surgical Oncology</i> , 2018, 25, 2596-2602.	1.5	55
46	Prophylactic Mastectomy in Patients with Atypical Breast Lesions. , 2018, , 147-157.		0
47	Alterations in the Immune Cell Composition in Premalignant Breast Tissue that Precede Breast Cancer Development. <i>Clinical Cancer Research</i> , 2017, 23, 3945-3952.	7.0	46
48	Multivariate model to identify women at low risk of cancer upgrade after a core needle biopsy diagnosis of atypical ductal hyperplasia. <i>Breast Cancer Research and Treatment</i> , 2017, 164, 295-304.	2.5	68
49	Mammographic breast density and risk of breast cancer in women with atypical hyperplasia: an observational cohort study from the Mayo Clinic Benign Breast Disease (BBD) cohort. <i>BMC Cancer</i> , 2017, 17, 84.	2.6	23
50	Breast Cancer Risk and Progressive Histology in Serial Benign Biopsies. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	6.3	10
51	Flat Epithelial Atypia on Core Biopsy and Upgrade to Cancer: a Systematic Review and Meta-Analysis. <i>Annals of Surgical Oncology</i> , 2017, 24, 3549-3558.	1.5	46
52	Postlactational involution biomarkers plasminogen and phospho-STAT3 are linked with active age-related lobular involution. <i>Breast Cancer Research and Treatment</i> , 2017, 166, 133-143.	2.5	0
53	A Validated Nomogram to Predict Upstaging of Ductal Carcinoma in Situ to Invasive Disease. <i>Annals of Surgical Oncology</i> , 2017, 24, 2915-2924.	1.5	47
54	Lobular Neoplasia and Atypical Ductal Hyperplasia on Core Biopsy: Current Surgical Management Recommendations. <i>Annals of Surgical Oncology</i> , 2017, 24, 2848-2854.	1.5	26

#	ARTICLE	IF	CITATIONS
55	Challenging Atypical Breast Lesions Including Flat Epithelial Atypia, Radial Scar, and Intraductal Papilloma. <i>Annals of Surgical Oncology</i> , 2017, 24, 2842-2847.	1.5	26
56	NanoString-based breast cancer risk prediction for women with sclerosing adenosis. <i>Breast Cancer Research and Treatment</i> , 2017, 166, 641-650.	2.5	10
57	Margin Proximity Correlates with Local Recurrence After Mastectomy for Patients Not Receiving Adjuvant Radiotherapy. <i>Annals of Surgical Oncology</i> , 2017, 24, 3148-3156.	1.5	14
58	Outcomes and feasibility of nipple-sparing mastectomy for node-positive breast cancer Patients. <i>American Journal of Surgery</i> , 2017, 213, 810-813.	1.8	9
59	The American Society of Breast Surgeons and Quality Payment Programs: Ranking, Defining, and Benchmarking More Than 1 Million Patient Quality Measure Encounters. <i>Annals of Surgical Oncology</i> , 2017, 24, 3093-3106.	1.5	15
60	Association between mammographic breast density and histologic features of benign breast disease. <i>Breast Cancer Research</i> , 2017, 19, 134.	5.0	24
61	Molecular targeting of the Aurora-A/SMAD5 oncogenic axis restores chemosensitivity in human breast cancer cells. <i>Oncotarget</i> , 2017, 8, 91803-91816.	1.8	23
62	A Picture is Worth a Thousand Words: Intraoperative Photography as a Quality Metric for Axillary Dissection. <i>Annals of Surgical Oncology</i> , 2016, 23, 3494-3500.	1.5	3
63	Standardized measures of lobular involution and subsequent breast cancer risk among women with benign breast disease: a nested case-control study. <i>Breast Cancer Research and Treatment</i> , 2016, 159, 163-172.	2.5	48
64	Contemporary operative management of T4 breast cancer. <i>Surgery</i> , 2016, 160, 1059-1069.	1.9	8
65	Measures of Appropriateness and Value for Breast Surgeons and Their Patients: The American Society of Breast Surgeons Choosing Wisely® Initiative. <i>Annals of Surgical Oncology</i> , 2016, 23, 3112-3118.	1.5	29
66	Feasibility and full-course dosimetry of an intraoperatively placed multichannel brachytherapy catheter for accelerated partial breast irradiation. <i>Brachytherapy</i> , 2016, 15, 796-803.	0.5	6
67	Contralateral Prophylactic Mastectomy for Women with T4 Locally Advanced Breast Cancer. <i>Annals of Surgical Oncology</i> , 2016, 23, 3365-3370.	1.5	7
68	Dense Breasts: What Do Our Patients Need to Be Told and Why?. <i>Annals of Surgical Oncology</i> , 2016, 23, 3119-3127.	1.5	3
69	Breast cancer risk by the extent and type of atypical hyperplasia. <i>Cancer</i> , 2016, 122, 3087-3088.	4.1	10
70	Extent of atypical hyperplasia stratifies breast cancer risk in 2 independent cohorts of women. <i>Cancer</i> , 2016, 122, 2971-2978.	4.1	48
71	The Microbiome of Aseptically Collected Human Breast Tissue in Benign and Malignant Disease. <i>Scientific Reports</i> , 2016, 6, 30751.	3.3	299
72	Clinicopathologic features of breast cancers that develop in women with previous benign breast disease. <i>Cancer</i> , 2016, 122, 378-385.	4.1	31

#	ARTICLE	IF	CITATIONS
73	Use of immediate breast reconstruction and choice for contralateral prophylactic mastectomy. <i>Surgery</i> , 2016, 159, 1199-1209.	1.9	39
74	A Novel Treatment Schedule for Rapid Completion of Surgery and Radiation in Early-Stage Breast Cancer. <i>Annals of Surgical Oncology</i> , 2016, 23, 3297-3303.	1.5	12
75	Natural history of age-related lobular involution and impact on breast cancer risk. <i>Breast Cancer Research and Treatment</i> , 2016, 155, 423-430.	2.5	29
76	Contralateral Prophylactic Mastectomy: Factors Predictive of Occult Malignancy or High-Risk Lesion and the Impact of MRI and Genetic Testing. <i>Annals of Surgical Oncology</i> , 2016, 23, 72-77.	1.5	14
77	Mucocele-like lesions of the breast: a clinical outcome and histologic analysis of 102 cases. <i>Human Pathology</i> , 2016, 49, 33-38.	2.0	29
78	Comparative Study of Liposomal Bupivacaine Versus Paravertebral Block for Pain Control Following Mastectomy with Immediate Tissue Expander Reconstruction. <i>Annals of Surgical Oncology</i> , 2016, 23, 465-470.	1.5	25
79	Infections after breast surgery: potential ways to reduce infection rates. <i>Breast Cancer Management</i> , 2015, 4, 17-24.	0.2	0
80	ER β Expression and Breast Cancer Risk Prediction for Women with Atypias. <i>Cancer Prevention Research</i> , 2015, 8, 1084-1092.	1.5	16
81	Flat epithelial atypia and risk of breast cancer: A Mayo cohort study. <i>Cancer</i> , 2015, 121, 1548-1555.	4.1	85
82	Model for Individualized Prediction of Breast Cancer Risk After a Benign Breast Biopsy. <i>Journal of Clinical Oncology</i> , 2015, 33, 923-929.	1.6	51
83	Atypical Hyperplasia of the Breast – Risk Assessment and Management Options. <i>New England Journal of Medicine</i> , 2015, 372, 78-89.	27.0	281
84	Introducing the SKIN Score: A Validated Scoring System to Assess Severity of Mastectomy Skin Flap Necrosis. <i>Annals of Surgical Oncology</i> , 2015, 22, 2925-2932.	1.5	42
85	Gene signature model for breast cancer risk prediction for women with sclerosing adenosis. <i>Breast Cancer Research and Treatment</i> , 2015, 152, 687-694.	2.5	11
86	Diffuse dermal angiomatosis of the breast: a series of 22 cases from a single institution. <i>Gland Surgery</i> , 2015, 4, 554-60.	1.1	17
87	Terminal Duct Lobular Unit Involution of the Normal Breast: Implications for Breast Cancer Etiology. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	6.3	67
88	Reasons for Re-Excision After Lumpectomy for Breast Cancer: Insight from the American Society of Breast Surgeons MasterySM Database. <i>Annals of Surgical Oncology</i> , 2014, 21, 3185-3191.	1.5	104
89	Understanding the Premalignant Potential of Atypical Hyperplasia through Its Natural History: A Longitudinal Cohort Study. <i>Cancer Prevention Research</i> , 2014, 7, 211-217.	1.5	192
90	Randomized Trial of Drain Antisepsis After Mastectomy and Immediate Prosthetic Breast Reconstruction. <i>Annals of Surgical Oncology</i> , 2014, 21, 3240-3248.	1.5	13

#	ARTICLE	IF	CITATIONS
91	Impact of analysis of frozen-section margin on reoperation rates in women undergoing lumpectomy for breast cancer: Evaluation of the National Surgical Quality Improvement Program data. <i>Surgery</i> , 2014, 156, 190-197.	1.9	90
92	Sclerosing adenosis and risk of breast cancer. <i>Breast Cancer Research and Treatment</i> , 2014, 144, 205-212.	2.5	72
93	Risk Factors Associated with Breast Lymphedema. <i>Annals of Surgical Oncology</i> , 2014, 21, 1202-1208.	1.5	48
94	Immune cell quantitation in normal breast tissue lobules with and without lobulitis. <i>Breast Cancer Research and Treatment</i> , 2014, 144, 539-549.	2.5	65
95	Aurora-A Mitotic Kinase Induces Endocrine Resistance through Down-Regulation of ER α Expression in Initially ER α + Breast Cancer Cells. <i>PLoS ONE</i> , 2014, 9, e96995.	2.5	30
96	Surgical Management of High-Risk Breast Lesions. <i>Surgical Clinics of North America</i> , 2013, 93, 329-340.	1.5	46
97	Should Re-excision Lumpectomy Rates Be a Quality Measure in Breast-Conserving Surgery?. <i>Annals of Surgical Oncology</i> , 2013, 20, 3180-3183.	1.5	18
98	Randomized Controlled Trial to Reduce Bacterial Colonization of Surgical Drains After Breast and Axillary Operations. <i>Annals of Surgery</i> , 2013, 258, 240-247.	4.2	63
99	Uncommon Benign Breast Abnormalities in Adolescents. <i>Seminars in Plastic Surgery</i> , 2013, 27, 026-028.	2.1	14
100	Incorporation of Sentinel Lymph Node Metastasis Size Into a Nomogram Predicting Nonsentinel Lymph Node Involvement in Breast Cancer Patients With a Positive Sentinel Lymph Node. <i>Annals of Surgery</i> , 2012, 255, 109-115.	4.2	116
101	A prospective study of breast lymphedema: frequency, symptoms, and quality of life. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 915-922.	2.5	47
102	Surgical Site Infection after Breast Surgery: Impact of 2010 CDC Reporting Guidelines. <i>Annals of Surgical Oncology</i> , 2012, 19, 4099-4103.	1.5	46
103	National Practice Patterns in Preoperative and Postoperative Antibiotic Prophylaxis in Breast Procedures Requiring Drains: Survey of the American Society of Breast Surgeons. <i>Annals of Surgical Oncology</i> , 2012, 19, 3205-3211.	1.5	36
104	Should axillary ultrasound be used in patients with a preoperative diagnosis of ductal carcinoma in situ?. <i>American Journal of Surgery</i> , 2012, 204, 290-293.	1.8	8
105	Histologic findings in normal breast tissues: comparison to reduction mammoplasty and benign breast disease tissues. <i>Breast Cancer Research and Treatment</i> , 2012, 133, 169-177.	2.5	64
106	An unusual presentation of breast cancer in a very young woman. <i>BMJ Case Reports</i> , 2011, 2011, bcr1220103590-bcr1220103590.	0.5	1
107	The Number of Axillary Lymph Nodes Involved with Metastatic Breast Cancer Does not Affect Outcome as Long as All Disease is Confined to the Sentinel Lymph Nodes. <i>Annals of Surgical Oncology</i> , 2011, 18, 86-93.	1.5	26
108	Cost-Effectiveness Analysis of Routine Frozen-Section Analysis of Breast Margins Compared with Reoperation for Positive Margins. <i>Annals of Surgical Oncology</i> , 2011, 18, 3204-3209.	1.5	74

#	ARTICLE	IF	CITATIONS
109	Axillary Recurrence in Breast Cancer Patients with Isolated Tumor Cells in the Sentinel Lymph Node [AJCC N0(i+)]. <i>Annals of Surgical Oncology</i> , 2010, 17, 2685-2689.	1.5	21
110	Predicting Four or More Metastatic Axillary Lymph Nodes in Patients with Sentinel Node-Positive Breast Cancer: Assessment of Existent Risk Scores. <i>Annals of Surgical Oncology</i> , 2010, 17, 2884-2891.	1.5	3
111	Pseudoangiomatous Stromal Hyperplasia and Breast Cancer Risk. <i>Annals of Surgical Oncology</i> , 2010, 17, 3269-3277.	1.5	52
112	Pure Tubular Carcinoma and Axillary Nodal Metastases. <i>Annals of Surgical Oncology</i> , 2010, 17, 338-342.	1.5	27
113	Ki67: a time-varying biomarker of risk of breast cancer in atypical hyperplasia. <i>Breast Cancer Research and Treatment</i> , 2010, 121, 431-437.	2.5	63
114	Evaluation of the Tyrer-Cuzick (International Breast Cancer Intervention Study) Model for Breast Cancer Risk Prediction in Women With Atypical Hyperplasia. <i>Journal of Clinical Oncology</i> , 2010, 28, 3591-3596.	1.6	103
115	Reply to S.L. Gomez et al. <i>Journal of Clinical Oncology</i> , 2010, 28, e158-e158.	1.6	0
116	Microbiology of Surgical Site Infections Complicating Breast Surgery. <i>Surgical Infections</i> , 2010, 11, 355-359.	1.4	23
117	Novel Breast Tissue Feature Strongly Associated With Risk of Breast Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 5893-5898.	1.6	44
118	Incidence of Clinically Significant Seroma after Breast and Axillary Surgery. <i>Journal of the American College of Surgeons</i> , 2009, 208, 148-150.	0.5	56
119	Assessment of the performance of the Stanford Online Calculator for the prediction of nonsentinel lymph node metastasis in sentinel lymph node-positive breast cancer patients. <i>Cancer</i> , 2009, 115, 4064-4070.	4.1	31
120	Lobular involution: localized phenomenon or field effect?. <i>Breast Cancer Research and Treatment</i> , 2009, 117, 193-196.	2.5	20
121	Refining risk assessment in women with atypical hyperplasia. <i>Current Breast Cancer Reports</i> , 2009, 1, 167-174.	1.0	1
122	Simple Prediction Models for Breast Cancer Patients with Solitary Positive Sentinel Nodes—are they Valid?. <i>Breast Journal</i> , 2009, 15, 610-614.	1.0	6
123	Postoperative Prophylactic Antibiotics and Surgical Site Infection Rates in Breast Surgery Patients. <i>Annals of Surgical Oncology</i> , 2009, 16, 2464-2469.	1.5	58
124	Complications associated with postoperative antibiotic prophylaxis after breast surgery. <i>American Journal of Surgery</i> , 2009, 198, 553-556.	1.8	21
125	Breast cancer risk in women with radial scars in benign breast biopsies. <i>Breast Cancer Research and Treatment</i> , 2008, 108, 167-174.	2.5	83
126	Sentinel node positive breast cancer patients who do not undergo axillary dissection: Are they different?. <i>Surgery</i> , 2008, 143, 641-647.	1.9	31

#	ARTICLE	IF	CITATIONS
127	Safety and technical success of methylene blue dye for lymphatic mapping in breast cancer. American Journal of Surgery, 2008, 196, 228-233.	1.8	76
128	Assessment of the Accuracy of the Gail Model in Women With Atypical Hyperplasia. Journal of Clinical Oncology, 2008, 26, 5374-5379.	1.6	94
129	Stratification of Breast Cancer Risk in Women With Atypia: A Mayo Cohort Study. Journal of Clinical Oncology, 2007, 25, 2671-2677.	1.6	226
130	A Multidisciplinary Approach to the Management of Breast Cancer, Part 1: Prevention and Diagnosis. Mayo Clinic Proceedings, 2007, 82, 999-1012.	3.0	39
131	Sentinel lymph node biopsy for breast cancer: How many nodes are enough?. Journal of Surgical Oncology, 2007, 96, 554-559.	1.7	67
132	Society of Surgical Oncology: Position Statement on Prophylactic Mastectomy. Approved by the Society of Surgical Oncology Executive Council, March 2007. Annals of Surgical Oncology, 2007, 14, 2425-2427.	1.5	119
133	Paget's disease of the breast: accuracy of preoperative assessment. Breast Cancer Research and Treatment, 2007, 102, 137-142.	2.5	44
134	Breast Cancer Presenting as Unilateral Arm Edema. Journal of General Internal Medicine, 2007, 22, 675-676.	2.6	10
135	Clinicopathologic Features Associated With Having Four or More Metastatic Axillary Nodes in Breast Cancer Patients With a Positive Sentinel Lymph Node. Annals of Surgical Oncology, 2006, 13, 36-44.	1.5	55
136	Sentinel lymph node biopsy for breast cancer: is two-site injection best?. Surgery, 2006, 139, 630-632.	1.9	2
137	Age-Related Lobular Involution and Risk of Breast Cancer. Journal of the National Cancer Institute, 2006, 98, 1600-1607.	6.3	218
138	Is Blue Dye Indicated for Sentinel Lymph Node Biopsy in Breast Cancer Patients With a Positive Lymphoscintigram?. Annals of Surgical Oncology, 2005, 12, 712-717.	1.5	19
139	Benign Breast Disease and the Risk of Breast Cancer. New England Journal of Medicine, 2005, 353, 229-237.	27.0	785
140	Nonsentinel node metastasis in breast cancer patients: assessment of an existing and a new predictive nomogram. American Journal of Surgery, 2005, 190, 543-550.	1.8	223
141	Clinicopathologic features of metastasis in nonsentinel lymph nodes of breast carcinoma patients. Cancer, 2003, 98, 2307-2315.	4.1	145
142	The Benefits of Local Anesthesia Used in Mastectomy Without Reconstruction. American Surgeon, 0, , 000313482210919.	0.8	0